AIMS/HYPOTHESIS: Type 2 diabetes is characterised by impaired glucose-stimulated insulin secretion (GSIS) from pancreatic islets. Since erythropoietin-producing hepatoma (Eph)-ephrin bidirectional signalling fine-tunes GSIS from pancreatic beta cells, we investigated Eph receptor tyrosine kinases (RTK) as potential drug targets for selectively increasing GSIS. METHODS: Insulin secretion assays were carried out using mouse and human pancreatic islets as well as mouse insulinoma (MIN6) cells in the presence or absence of two Eph RTK inhibitors. Furthermore, the most potent inhibitor was injected into mice to evaluate its effects on glucose tolerance and plasma insulin levels. RESULTS: We showed that the Eph RTK inhibitors selectively increased GSIS from MIN6 cells as well as mouse and human islets. Our results also showed that the insulin secretory effects of these compounds required Eph-ephrin signalling. Finally, pharmacological inhibition of Eph receptor signalling improved glucose tolerance in mice. CONCLUSIONS/ INTERPRETATION: We showed for the first time that Eph RTKs represent targets for small molecules to selectively increase GSIS and improve glucose tolerance.
AIMS/HYPOTHESIS: Type 2 diabetes is characterised by impaired glucose-stimulated insulin secretion (GSIS) from pancreatic islets. Since erythropoietin-producing hepatoma (Eph)-ephrin bidirectional signalling fine-tunes GSIS from pancreatic beta cells, we investigated Eph receptor tyrosine kinases (RTK) as potential drug targets for selectively increasing GSIS. METHODS: Insulin secretion assays were carried out using mouse and humanpancreatic islets as well as mouseinsulinoma (MIN6) cells in the presence or absence of two Eph RTK inhibitors. Furthermore, the most potent inhibitor was injected into mice to evaluate its effects on glucose tolerance and plasma insulin levels. RESULTS: We showed that the Eph RTK inhibitors selectively increased GSIS from MIN6 cells as well as mouse and human islets. Our results also showed that the insulin secretory effects of these compounds required Eph-ephrin signalling. Finally, pharmacological inhibition of Eph receptor signalling improved glucose tolerance in mice. CONCLUSIONS/ INTERPRETATION: We showed for the first time that Eph RTKs represent targets for small molecules to selectively increase GSIS and improve glucose tolerance.
Authors: Kathrin Maedler; Joachim Størling; Jeppe Sturis; Richard A Zuellig; Giatgen A Spinas; Per O G Arkhammar; Thomas Mandrup-Poulsen; Marc Y Donath Journal: Diabetes Date: 2004-07 Impact factor: 9.461
Authors: Jan Marquard; Silke Otter; Alena Welters; Alin Stirban; Annelie Fischer; Jan Eglinger; Diran Herebian; Olaf Kletke; Maša Skelin Klemen; Andraž Stožer; Stephan Wnendt; Lorenzo Piemonti; Martin Köhler; Jorge Ferrer; Bernard Thorens; Freimut Schliess; Marjan Slak Rupnik; Tim Heise; Per-Olof Berggren; Nikolaj Klöcker; Thomas Meissner; Ertan Mayatepek; Daniel Eberhard; Martin Kragl; Eckhard Lammert Journal: Nat Med Date: 2015-03-16 Impact factor: 53.440
Authors: Beáta B Tóth; Rini Arianti; Abhirup Shaw; Attila Vámos; Zoltán Veréb; Szilárd Póliska; Ferenc Győry; Zsolt Bacso; László Fésüs; Endre Kristóf Journal: Cells Date: 2020-04-16 Impact factor: 6.600
Authors: Francesco Volta; M Julia Scerbo; Anett Seelig; Robert Wagner; Nils O'Brien; Felicia Gerst; Andreas Fritsche; Hans-Ulrich Häring; Anja Zeigerer; Susanne Ullrich; Jantje M Gerdes Journal: Nat Commun Date: 2019-12-12 Impact factor: 14.919